Acute coronary syndrome
270 results
31 - 130
Acute coronary syndrome 
Clinical decision helpful in diagnosis of acute coronary syndrome in primary care
Hyperbaric oxygen therapy for acute coronary syndrome- Statins for acute coronary syndrome
- Presence of risk factors doesn't predict acute coronary syndrome
- Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome
- Escitalopram reduces risk of adverse cardiac events in adults with depression and acute coronary syndrome
- Early CT angiography for suspected acute coronary syndrome reduces further ischemic testing; no effect on long-term clinical outcomes
- PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
- For treatment of acute coronary syndrome, prasugrel is better than ticagrelor at preventing recurrent MIs at 1 year
- Chronic coronary syndrome (coronary heart disease)
- Dabigatran associated with increased risk of coronary events
- Patients with non-ST-elevation acute coronary syndromes do not need immediate intervention
- Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes: Cochrane systematic review
- Additional testing of limited benefit in patients with new-onset chest pain
- Coronary CT angiogram allows for safe discharge of low-risk patients with chest pain
- FDA: Clopidogrel/aspirin does not decrease overall mortality
- Faster discharge but more downstream testing with use of CCTA in ED
- HET score: atypical chest pain + normal ECG + normal troponin = no acute coronary event
- Genotype-guided selection of oral P2Y12 inhibitor therapy no better than standard therapy after PCI for ACS or stable CAD
- For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
- Ruling out acute myocardial infarction based on patient characteristics
- Intensive lipid lowering reduces mortality following ACS
- Bivalirudin = abciximab + heparin for non-STEMI
- Pain severity does not predict outcomes with AMI
- Intensive lipid lowering adds additional benefit
- Signs and symptoms not helpful in diagnosis of AMI/ACS
- Improved outcomes with early invasive strategy for ACS? Maybe, maybe not.
- Low-dose rivaroxaban improves outcomes in patients with ACS (ATLAS)
- ED chest pain protocol is safe and efficient
- No reduction in postdischarge medication errors after pharmacist-led intervention
- Routine stress testing after negative biomarker testing seldom helpful
- Two-hour protocol identifies patients at low risk of ACS
- Better medication adherence with intervention; clinical outcomes unchanged
- Flu vaccine reduces risk of adverse CV events in high-risk patients
- Dyspepsia
- Early invasive therapy better for non-ST ACS
- Concomitant use of clopidogrel and a PPI may increase risk of adverse CHD outcomes
- Apixaban increases bleeding with no benefit in high-risk patients with ACS
- ACC/AHA guidelines on dual antiplatelet therapy
- CCTA reduces need for hospitalization in low to moderate risk patients in ED
- Fondaparinux for acute coronary syndromes
- In low-risk patients with ACS, noninvasive testing adds little to clinical evaluation
- Antithrombotic agents in primary health care
- In ACS, 5 yrs of invasive tx decreases MI but not all cause mortality (FRISC-II)
- Platelet-function testing doesn't improve outcomes in elderly patients with stents after ACS
- ACS risk similar with normal ECG performed during presence or absence of chest pain
- Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
- Evacetrapib increases HDL but does nothing for patient-oriented outcomes
- Interpretation of adult ECG
- Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy